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In this issue of the Journal, Levy et al. [1] report on the
clinically relevant results of a cross-sectional prospective
study, performed by a multidisciplinary team of researchers
between 2009 and 2014, and aimed at detecting dietary and
herbal supplements (DHSs) use among patients hospital-
ized at the Bnai Zion Medical Center in Israel.
The innovative aspect of Levy’s study was represented
by the attempt to identify through the administration of a
dedicated questionnaire, not only the prevalence of DHS
use among hospital patients, but also the possible DHS–
DHS interactions in the inpatient study population. Indeed,
the hypothesis of the authors is that DHS–DHS interaction
may be a cause for either hospitalization or for worsening
of an underlying comorbidity. The rate of respondents to
the questionnaire was rather good, reaching almost 91 %
(927 out of the 1020 delivered questionnaires). Interest-
ingly enough, almost 50 % of the respondents overall
reported the use of some 89 different DHSs. The potential
risks for DHS–DHS interactions were analyzed through
univariate and multivariate logistics regression analyses.
In their study, Levy et al. identified potential DHS–DHS
interactions in only 59 patients, accounting for 13 % of
respondents, with the most common potential effects being
hypercalcemia, hypotension, bleeding, and hypoglycemia.
In three patients, these negative interactions were associ-
ated with either hospitalization or adverse event during
hospital stay. With respect to their working hypothesis, the
authors then conclude that more than 6 % of patients
hospitalized in a general hospital have the potential for
developing DHS–DHS interaction.
Although the study has limitations, some of which are
acknowledged by the author themselves in the discussion,
the report by Levy et al. raises a relevant issue in the
modern scenario of clinical medicine, i.e., the rising con-
sumption of dietary supplements by patients in the com-
munity, as a key component of complementary and
alternative medicines (CAMs) [2].
The use of CAM such as herbal medicines and dietary
supplements is well documented, and is particularly com-
mon in older adults [3] and in patients with chronic dis-
eases including cancer [2]. Just to give an estimate of the
phenomenon, it can be considered that the number of
dietary supplements in the USA grew from 4000 in 1994 to
approximately 75,000 in 2008 [4], for many of which
manufacturers evade regulatory limits [5].
The growing use of herbal and dietary supplements is
favored by the ease of internet-acquired information and
internet trading, coupled with the diffuse perception that
while conventional medicines are often misprescribed,
overprescribed, ineffective or dangerous [6], and herbal
and dietary remedies represent a natural and, therefore,
safer therapeutic approach to maladies, especially chronic
and incurable diseases. For these reasons, as correctly
pointed out by Levy et al. [1], their use is very commonly
not known by doctors [7, 8]. Indeed, Levy et al. report that
in their study, DHS use was not reported in 89 % of the
medical files of the studied patients, and that only 18 % of
the DHSs involved in the interactions were documented.
These findings highlight two important aspects that
should not be overlooked in our everyday clinical practice.
On the one side, is the reluctance of patients to advise their
physician about the regular use of DHS, since this infor-
mation is deemed not important for the doctor. On the other
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side, is the need to train medical students and residents to
systematically and accurately include information about
the use of dietary supplements in the pharmacological
history of in- and outpatients they are taking care of. The
latter appears particularly relevant when considering the
multiethnic scenario of modern clinical medicine [9] and
the culture-based wide use of herbal remedies in non-
European, and particularly in Asian populations [10]. This
represents a real challenge clinical medicine will have to
undertake in the next few years.
A category of patients who appear vulnerable and
exposed to the risks of health- or life-threatening interac-
tions of dietary supplements is represented by cancer
patients, who are particularly keen to refer to CAM
worldwide, [2] and to take herbal medicines and dietary
supplements in the attempt to attenuate or counteract the
side effects of conventional antineoplastic treatments, or
even in the hope of enhancing their therapeutic efficacy
[5, 11].
Amazingly enough, almost 60 % of people consuming
dietary supplements do so to prevent or treat cancer [5],
which explains why Americans spent more than 36 billion
USD on dietary supplements in 2014 [5]. In the United
States, almost half of cancer patients start taking dietary
supplements soon after receiving a diagnosis of cancer
[12]. Although solid clinical data are lacking [2], concern
still exists about the potential interactions of dietary
supplements with conventional therapies (either radio-
chemo- or biological therapies) especially with
chemotherapy drugs with a narrow therapeutic index, [2]
or with therapies based on the induction of reactive
oxygen species [13].
In conclusion, the conventional clinical medicine is
progressively facing the growing diffusion of CAM, with
treatments based on the claimed efficacy of DHS to exert
positive effects in patients with acute and chronic dis-
eases, including cancer. Therapeutic or preventative
claims for most DHS are based on evidence from phase 2
trials, which in the majority of cases fail to be confirmed
in phase 3 clinical trials [5]. However, DHSs fuel a very
florid market, since patients often base significant
expectations on these treatments, reporting subjective
improvement in disease- or treatment-related symptoms.
This has clinical and ethical implications that should be
carefully evaluated by well-trained, modern physicians.
Modes of actions, possible biologically plausible benefits,
possible DHD–DHS and DHS–drug interactions and
patient’s expectations should all be taken into account
when suggesting a patient to continue or withdraw a
DHS-based treatment. Provided that we have taken note
of it in the medical history.
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